Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sonnet BioTherapeutics stock

Own Sonnet BioTherapeutics stock in just a few minutes.

Sonnet BioTherapeutics Holdings, Inc is a biotechnology business based in the US. Sonnet BioTherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Sonnet BioTherapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Sonnet BioTherapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SONN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Sonnet BioTherapeutics share price

Use our graph to track the performance of SONN stocks over time.

Sonnet BioTherapeutics shares at a glance

Information last updated 2021-04-21.
52-week range$1.81 - $5.48
50-day moving average $2.27
200-day moving average $2.53
Wall St. target price$8.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-66.46

Buy Sonnet BioTherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sonnet BioTherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sonnet BioTherapeutics financials

Gross profit TTM $0
Return on assets TTM -651.77%
Return on equity TTM -27822.18%
Profit margin 0%
Book value N/A
Market capitalisation $35.8 million

TTM: trailing 12 months

Shorting Sonnet BioTherapeutics shares

There are currently 383,894 Sonnet BioTherapeutics shares held short by investors – that's known as Sonnet BioTherapeutics's "short interest". This figure is 54.5% down from 843,078 last month.

There are a few different ways that this level of interest in shorting Sonnet BioTherapeutics shares can be evaluated.

Sonnet BioTherapeutics's "short interest ratio" (SIR)

Sonnet BioTherapeutics's "short interest ratio" (SIR) is the quantity of Sonnet BioTherapeutics shares currently shorted divided by the average quantity of Sonnet BioTherapeutics shares traded daily (recently around 959735). Sonnet BioTherapeutics's SIR currently stands at 0.4. In other words for every 100,000 Sonnet BioTherapeutics shares traded daily on the market, roughly 400 shares are currently held short.

However Sonnet BioTherapeutics's short interest can also be evaluated against the total number of Sonnet BioTherapeutics shares, or, against the total number of tradable Sonnet BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sonnet BioTherapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sonnet BioTherapeutics shares in existence, roughly 20 shares are currently held short) or 0.0235% of the tradable shares (for every 100,000 tradable Sonnet BioTherapeutics shares, roughly 24 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sonnet BioTherapeutics.

Find out more about how you can short Sonnet BioTherapeutics stock.

Sonnet BioTherapeutics share dividends

We're not expecting Sonnet BioTherapeutics to pay a dividend over the next 12 months.

Have Sonnet BioTherapeutics's shares ever split?

Sonnet BioTherapeutics's shares were split on a 1:26 basis on 1 April 2020. So if you had owned 26 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet BioTherapeutics shares – just the quantity. However, indirectly, the new 2500% higher share price could have impacted the market appetite for Sonnet BioTherapeutics shares which in turn could have impacted Sonnet BioTherapeutics's share price.

Sonnet BioTherapeutics overview

Sonnet BioTherapeutics Holdings, Inc. , an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site